Enfortumab vedotin-induced cutaneous toxicities and their association with survival in urothelial carcinoma

作者：E. Lee, Ralina Karagenova, Charles Lu, Parisa Farokh, Marjan Azin, Federico Repetto, Soma Jobbagy, Rosalynn M. Nazarian, Kerry Reynolds, Shadmehr Demehri, Philip J. Saylor, Lirit Fuksman, Yevgeniy R. Semenov · 发表于：medRxiv · 年份：2026 · DOI：10.64898/2026.05.19.26353579 · 被引用次数：1 · 研究领域：Bladder and Urothelial Cancer Treatments、Nonmelanoma Skin Cancer Studies、Dermatology and Skin Diseases

Abstract Key Points Question Among patients with advanced or metastatic urothelial cancer treated with enfortumab vedotin (EV), is development of EV-induced cutaneous adverse events (cAEs) associated with improved survival, and how does this association compare with cutaneous immune-related adverse events (cirAEs)? Findings In a multi-institutional retrospective cohort study, EV-induced cAEs were associated with significantly progression-free survival (hazard ratio, 0.60; 95% CI 0.31-0.67, p<0.001) and overall survival (hazard ratio, 0.46; 95% CI 0.31-0.67, p<0.001) across landmark analyses. Meaning EV-induced cAEs are independently associated with improved survival in patients, suggesting potential prognostic value during treatment of advanced urothelial cancer. Importance Enfortumab vedotin (EV) is an antibody-drug conjugate approved for the treatment of locally advanced or metastatic urothelial cancer (la/mUC). Cutaneous adverse events (cAEs) are common during EV therapy, with prior studies suggesting an association between EV-related cAEs and improved survival; however, there is insufficient data to delineate the survival benefit of EV-induced cAEs from those associated with concurrent immune checkpoint inhibitors (ICIs). Objective This study aims to evaluate the association of EV-induced cAEs and survival, and to characterize the timing and morphology of EV-induced cAEs. Design We conducted a multi-institutional retrospective study of patients with la/mUC treated w...